227 related articles for article (PubMed ID: 33450669)
1. Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan.
Takeshita M; Nishina N; Moriyama S; Takahashi Y; Uwamino Y; Nagata M; Aoki W; Masaki K; Ishii M; Saya H; Kondo Y; Kaneko Y; Suzuki K; Fukunaga K; Takeuchi T;
Virology; 2021 Mar; 555():35-43. PubMed ID: 33450669
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus.
Dogan M; Kozhaya L; Placek L; Gunter C; Yigit M; Hardy R; Plassmeyer M; Coatney P; Lillard K; Bukhari Z; Kleinberg M; Hayes C; Arditi M; Klapper E; Merin N; Liang BT; Gupta R; Alpan O; Unutmaz D
Commun Biol; 2021 Jan; 4(1):129. PubMed ID: 33514825
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.
Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B
Front Immunol; 2021; 12():614436. PubMed ID: 33790892
[TBL] [Abstract][Full Text] [Related]
4. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
[TBL] [Abstract][Full Text] [Related]
5. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
[TBL] [Abstract][Full Text] [Related]
6. Development of a quantitative COVID-19 multiplex assay and its use for serological surveillance in a low SARS-CoV-2 incidence community.
Guarino C; Larson E; Babasyan S; Rollins A; Joshi LR; Laverack M; Parrilla L; Plocharczyk E; Diel DG; Wagner B
PLoS One; 2022; 17(1):e0262868. PubMed ID: 35061843
[TBL] [Abstract][Full Text] [Related]
7. A Multiplex Microsphere IgG Assay for SARS-CoV-2 Using ACE2-Mediated Inhibition as a Surrogate for Neutralization.
Cameron A; Porterfield CA; Byron LD; Wang J; Pearson Z; Bohrhunter JL; Cardillo AB; Ryan-Muntz L; Sorensen RA; Caserta MT; Angeloni S; Hardy DJ; Zand MS; Pecora ND
J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33139422
[TBL] [Abstract][Full Text] [Related]
8. Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection.
Manisty C; Treibel TA; Jensen M; Semper A; Joy G; Gupta RK; Cutino-Moguel T; Andiapen M; Jones J; Taylor S; Otter A; Pade C; Gibbons J; Lee J; Bacon J; Thomas S; Moon C; Jones M; Williams D; Lambourne J; Fontana M; Altmann DM; Boyton R; Maini M; McKnight A; Chain B; Noursadeghi M; Moon JC
EBioMedicine; 2021 Mar; 65():103259. PubMed ID: 33662833
[TBL] [Abstract][Full Text] [Related]
9. A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics.
Jalkanen P; Pasternack A; Maljanen S; Melén K; Kolehmainen P; Huttunen M; Lundberg R; Tripathi L; Khan H; Ritvos MA; Naves R; Haveri A; Österlund P; Kuivanen S; Jääskeläinen AJ; Kurkela S; Lappalainen M; Rantasärkkä K; Vuorinen T; Hytönen J; Waris M; Tauriainen S; Ritvos O; Kakkola L; Julkunen I
J Infect Dis; 2021 Jul; 224(2):218-228. PubMed ID: 33905505
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain.
Bayarri-Olmos R; Idorn M; Rosbjerg A; Pérez-Alós L; Hansen CB; Johnsen LB; Helgstrand C; Zosel F; Bjelke JR; Öberg FK; Søgaard M; Paludan SR; Bak-Thomsen T; Jardine JG; Skjoedt MO; Garred P
J Immunol; 2021 Aug; 207(3):878-887. PubMed ID: 34301847
[TBL] [Abstract][Full Text] [Related]
11. IgG Antibodies Develop to Spike but Not to the Nucleocapsid Viral Protein in Many Asymptomatic and Light COVID-19 Cases.
Tutukina M; Kaznadzey A; Kireeva M; Mazo I
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696374
[TBL] [Abstract][Full Text] [Related]
12. Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study.
Griffante G; Chandel S; Ferrante D; Caneparo V; Capello D; Bettio V; Borgogna C; Aleni C; Esposito S; Sarro A; Vasile A; Comba M; Testa T; Cotrupi G; De Andrea M; Bortoluzzi S; Gariglio M
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835076
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic.
Edlow AG; Li JZ; Collier AY; Atyeo C; James KE; Boatin AA; Gray KJ; Bordt EA; Shook LL; Yonker LM; Fasano A; Diouf K; Croul N; Devane S; Yockey LJ; Lima R; Shui J; Matute JD; Lerou PH; Akinwunmi BO; Schmidt A; Feldman J; Hauser BM; Caradonna TM; De la Flor D; D'Avino P; Regan J; Corry H; Coxen K; Fajnzylber J; Pepin D; Seaman MS; Barouch DH; Walker BD; Yu XG; Kaimal AJ; Roberts DJ; Alter G
JAMA Netw Open; 2020 Dec; 3(12):e2030455. PubMed ID: 33351086
[TBL] [Abstract][Full Text] [Related]
14. Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort.
Rockstroh A; Wolf J; Fertey J; Kalbitz S; Schroth S; Lübbert C; Ulbert S; Borte S
Emerg Microbes Infect; 2021 Dec; 10(1):774-781. PubMed ID: 33830901
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition.
Maciola AK; La Raja M; Pacenti M; Salata C; De Silvestro G; Rosato A; Pasqual G
Front Immunol; 2022; 13():830710. PubMed ID: 35173741
[TBL] [Abstract][Full Text] [Related]
16. Pre-pandemic antibodies screening against SARS-CoV-2 and virus detection among children diagnosed with eruptive fevers.
Najimi N; Tajount L; Regragui Z; Remz C; Ait-Lhaj-Mhand R; Kadi C; Belayachi L; Seghrouchni F; Nadia Dakka ; El Hassani RA; Elharti E; Oumzil H; Bakri Y
Int J Immunopathol Pharmacol; 2024; 38():3946320241260633. PubMed ID: 38836458
[TBL] [Abstract][Full Text] [Related]
17. The complexities of SARS-CoV-2 serology.
Houlihan CF; Beale R
Lancet Infect Dis; 2020 Dec; 20(12):1350-1351. PubMed ID: 32979317
[No Abstract] [Full Text] [Related]
18. SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike.
Guthmiller JJ; Stovicek O; Wang J; Changrob S; Li L; Halfmann P; Zheng NY; Utset H; Stamper CT; Dugan HL; Miller WD; Huang M; Dai YN; Nelson CA; Hall PD; Jansen M; Shanmugarajah K; Donington JS; Krammer F; Fremont DH; Joachimiak A; Kawaoka Y; Tesic V; Madariaga ML; Wilson PC
mBio; 2021 Jan; 12(1):. PubMed ID: 33468695
[TBL] [Abstract][Full Text] [Related]
19. Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays.
Tang MS; Case JB; Franks CE; Chen RE; Anderson NW; Henderson JP; Diamond MS; Gronowski AM; Farnsworth CW
Clin Chem; 2020 Dec; 66(12):1538-1547. PubMed ID: 32894750
[TBL] [Abstract][Full Text] [Related]
20. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers.
Irsara C; Egger AE; Prokop W; Nairz M; Loacker L; Sahanic S; Pizzini A; Sonnweber T; Holzer B; Mayer W; Schennach H; Loeffler-Ragg J; Bellmann-Weiler R; Hartmann B; Tancevski I; Weiss G; Binder CJ; Anliker M; Griesmacher A; Hoermann G
Clin Chem Lab Med; 2021 Jul; 59(8):1453-1462. PubMed ID: 33837679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
